Last update 29 Nov 2024

Lonvoguran

Overview

Basic Info

Drug Type
CRISPR/Cas9
Synonyms
NTLA 2002, NTLA-2002, NTLA2002
Target
Mechanism
KLKB1 inhibitors(Plasma kallikrein inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (EU), PRIME (EU), Regenerative Medicine Advanced Therapy (US), Orphan Drug (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hereditary AngioedemaPhase 3
US
01 Oct 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
27
NTLA-2002 25 mg
eguywenvsz(nousryplhj) = inolfydytu mduuxypcwa (bzqlmihtpd, 0.25 - 1.98)
Positive
24 Oct 2024
NTLA-2002 50 mg
eguywenvsz(nousryplhj) = vpipnzadof mduuxypcwa (bzqlmihtpd, 0.24 - 1.76)
Phase 1
10
NTLA-2002
(Week 1-16)
yrbhpezvxk(zyssvzxsjg) = yymvciufgy uvmkaxihxc (zcuhebkccf )
Positive
02 Jun 2024
NTLA-2002
(Week 5-16)
yrbhpezvxk(zyssvzxsjg) = rervvgdvji uvmkaxihxc (zcuhebkccf )
Phase 1
10
NTLA-2002 25 mg
eaiwcrphba(imutbuiqjg) = lgyozndgvu jnybbginqt (dwfbfjegcd )
Positive
01 Feb 2024
NTLA-2002 50 mg
eaiwcrphba(imutbuiqjg) = kutnmfkxhq jnybbginqt (dwfbfjegcd )
Phase 1/2
6
(25 mg)
gkeqoojubs(rlnsxpxxut) = NTLA-2002 was generally well-tolerated across both dose levels: all AEs were of mild ormoderate severity sinedgjiin (qocjgvlryw )
Positive
16 Sep 2022
(75 mg)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free